Organic Revenue Growth: 5% with contributions from both Care Delivery and Care Enablement. Operating Income Growth: 11% increase, consistent with the expected phasing of the full year outlook. Net Leverage Ratio: Improved to 2.8x, below the self-imposed target range. Care Enablement Margin: Improved to 8.3%, entering the target margin band of 8% to 12%. Same Market Treatment Growth (U.S.): Stable, with a 0.5% plus expected growth for 2025. Same Market Treatment Growth (International): Accelerated to 2.5%. Lives Under Management: Increased from around 130,000 to around 148,000 by the end of March. Special Items Impact: Negatively affected group operating income by EUR126 million. Operating Cash Flow: Increased by 28% against last year's quarter due to improved operating working capital. Bond Issuance: Placed 2 bond tranches with an aggregate volume of EUR1.1 billion.

Warning! GuruFocus has detected 10 Warning Signs with FMS.

Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Fresenius Medical Care AG (NYSE:FMS) reported strong organic revenue growth of 5% in Q1 2025, driven by both Care Delivery and Care Enablement segments. The FME25 transformation program delivered EUR68 million in additional sustainable savings, contributing to the company's financial health. Operating income grew by 11%, positioning the company well for future quarters. The net leverage ratio improved to 2.8x, below the self-imposed target range, indicating strong financial discipline. Care Enablement segment achieved a margin of 8.3%, entering its target margin band of 8% to 12% for the first time.

Negative Points

The severe flu season led to increased missed treatments, impacting same market treatment growth in the U.S. Divestitures negatively impacted revenue development by 260 basis points. Special items, including costs related to portfolio optimization and the FME25 transformation program, negatively affected group operating income by EUR126 million. Labor and inflation costs offset some of the earnings developments in the Care Delivery segment. The company faced a headwind from one less dialysis day in the quarter, affecting absolute volume development and utilization.

Q & A Highlights

Q: What are you seeing in April trading in the U.S., and how does this impact your confidence in the full-year guidance? A: The flu season hit hard in February and March, but we are encouraged by the underlying referrals, which are a strong leading indicator. We expect the mortality effect to show with a 6- to 8-week lag. We are confident in our positive trajectory and maintaining our 0.5% growth guidance for the year. - Helen Giza, CEO

Story Continues

Q: Can you provide an update on the revenue per treatment trend in the U.S. and its sustainability? A: We are seeing continued price and mix improvement, supported by the PPS rate increase and moderate price increases across the payer portfolio. This trend is developing in line with our expectations. - Helen Giza, CEO

Q: How are you pitching the HDF treatment to competitor clinics, and what are the operational benefits? A: HDF offers significant mortality improvement and operational benefits, such as simpler use, no need for saline, quicker clean downtime, and reduced training time. We are excited about its potential and will provide more details at our Capital Markets Day. - Helen Giza, CEO

Q: What is the impact of the current foreign exchange environment on your financials? A: In Q1, we had a positive FX tailwind with an average rate of 1.05. If the euro-U.S. dollar remains at current levels, we expect a 2% to 3% headwind on both top and bottom lines for the full fiscal year 2025. - Martin Fischer, CFO

Q: Can you discuss the remaining FME25 savings expected for this year and any potential divestitures? A: We started well with EUR68 million in savings and expect further contributions from Care Enablement and G&A functions. Regarding divestitures, we are mostly done, but will continue to review our portfolio for performance. - Martin Fischer, CFO and Helen Giza, CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments